KRAS and colorectal carcinoma: From an anti-VEGF targeted therapy point of view, it may be noted that VEGFA was significantly up-regulated in CRC compared to corresponding normal tissue (see Figure 3 for two different probes on the array) both for tumors with the KRAS wild-type and tumors with the KRAS mutation and the magnitude of up-regulation was not different (interaction p-value > 0.05 for both the probes).